Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Excretion, and Metabolism of [14C]PF-07265803 in Healthy Males
NCT05286281Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emprumapimod in dilated cardiomyopathy (DCM), sponsored by Pfizer. Primary endpoints: Total Recovery of Radioactivity in Urine up to 14 days, Total Recovery of Radioactivity in Feces up to 14 days and 4 more. Started Mar 2022; status: completed.
02
Drugs
emprumapimod
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT05286281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286281.